SuperworthAlnylam Pharmaceuticals profit margin ALNY
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 16.8%
- Operating margin, 12 months
- 20.8%
- Net margin on a year earlier
- +28.4 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, Alnylam Pharmaceuticals kept 16.8% of its revenue as net profit, with an operating margin of 20.8% and a gross margin of 79.7%.
The median for 10 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 9.3% | 13.5% | 81.6% |
| FY2024 | −12.4% | −7.9% | 85.6% |
| FY2023 | −24.1% | −15.4% | 83.0% |
| FY2022 | n/a | −75.7% | 83.7% |
| FY2021 | n/a | −83.9% | 83.4% |
| FY2020 | n/a | n/a | 84.2% |
| FY2019 | n/a | n/a | 88.6% |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | −69.7% | −66.2% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 16.8% | +28.4 pts | 20.8% | |
| Q1 FY26 | 13.3% | +23.1 pts | 17.5% | |
| Q4 FY25 | 9.3% | +21.7 pts | 13.5% | |
| Q3 FY25 | 2.4% | +18.3 pts | 8.2% | |
| Q2 FY25 | −11.6% | −8.5 pts | −7.3% | |
| Q1 FY25 | −9.8% | +6.8 pts | −4.9% | |
| Q4 FY24 | −12.4% | +11.7 pts | −7.9% | |
| Q3 FY24 | −15.9% | +13.7 pts | −9.0% | |
| Q2 FY24 | −3.1% | +82.8 pts | 4.4% | |
| Q1 FY24 | −16.6% | +76.6 pts | −8.8% | |
| Q4 FY23 | −24.1% | n/a | −15.4% | |
| Q3 FY23 | −29.6% | n/a | −20.6% |
Against its peers
Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| ALNYAlnylam Pharmaceuticals | 16.8% |
| UTHRUnited Therapeutics | 41.6% |
| INCYIncyte | 27.7% |
| ONCBeOne Medicines | 10.7% |
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| TECHBIO-TECHNE | 15.0% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| Peer median | 26.3% |
Where Alnylam Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Alnylam Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.